Your browser doesn't support javascript.
loading
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Strober, B E; Langley, R G B; Menter, A; Magid, M; Porter, B; Fox, T; Safi, J; Papavassilis, C.
Afiliação
  • Strober BE; Department of Dermatology, University of Connecticut Health Center, Farmington, CT, U.S.A.
  • Langley RGB; Probity Medical Research, Waterloo, ON, Canada.
  • Menter A; Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, NS, Canada.
  • Magid M; Division of Dermatology, Baylor University Medical Center, Dallas, TX, U.S.A.
  • Porter B; Department of Psychiatry, UT Austin at Seton Family of Hospitals, Austin, TX, U.S.A.
  • Fox T; Novartis Pharmaceuticals, East Hanover, NJ, U.S.A.
  • Safi J; Novartis Pharma AG, Basel, Switzerland.
  • Papavassilis C; Novartis Pharmaceuticals, East Hanover, NJ, U.S.A.
Br J Dermatol ; 178(2): e105-e107, 2018 02.
Article em En | MEDLINE | ID: mdl-28991372

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Transtorno Depressivo / Fármacos Dermatológicos / Ideação Suicida / Anticorpos Monoclonais Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Transtorno Depressivo / Fármacos Dermatológicos / Ideação Suicida / Anticorpos Monoclonais Idioma: En Ano de publicação: 2018 Tipo de documento: Article